AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00795210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
Study NCT00795210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone Releasing Hormone
Description: Tesamorelin (GHRH) 2mg SC QD x 2 weeks
Study NCT01856348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT05025904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (rt-fMRI NFB)
Description: Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
Study NCT04427761 — intervention group
Intervention type: BEHAVIORAL
Intervention: Measurement of Transitions in Cancer Scale (MOT-CA) Survey
Description: These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
Study NCT04427761 — intervention group
Intervention type: BEHAVIORAL
Intervention: Distress Thermometer Survey
Description: These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
Study NCT03726697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tahneek
Description: A single dose of soft date containing glucose equivalent to 200mg/kg at 1 h after birth will be massaged into the buccal mucosa of the palate and cheek from right to left side, until the date paste is fully absorbed
Study NCT05025904 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Сognitive behavioral therapy (CBT)
Description: A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
Study NCT05025904 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EEG neurofeedback (EEG NFB)
Description: EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
Study NCT00326118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b and meningococcal serogroup C (vaccine)
Description: One intramuscular dose at 12-18 months of age
Study NCT00326118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix™
Description: One subcutaneous dose at 12-18 months of age
Study NCT00326118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix™
Description: One subcutaneous dose at 12-18 months of age
Study NCT00326118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: One intramuscular dose at 12-18 months of age.
Study NCT00326118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose at 12-18 months of age
Study NCT03363724 — intervention group
Intervention type: OTHER
Intervention: HaGuide version 1.0 software module
Study NCT04426188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heading series
Description: 10 headers from machine-projected soccer balls at standardized speeds
Study NCT04426188 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Heading series
Description: 10 headers from machine-projected soccer balls at standardized speeds
Study NCT04426188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Brain MRI before and after a series
Study NCT04426188 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Brain MRI before and after a series
Study NCT04426188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive computerized assessment
Description: Cognitive evaluation carried out with two computerized tools
Study NCT04426188 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive computerized assessment
Description: Cognitive evaluation carried out with two computerized tools
Study NCT04426188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiological records
Description: Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)
Study NCT04426188 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electrophysiological records
Description: Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)
Study NCT04426188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamometer
Description: Measure of the strength of the neck muscles using a dynamometer
Study NCT04426188 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dynamometer
Description: Measure of the strength of the neck muscles using a dynamometer
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT02021019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation
Study NCT01808508 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
Study NCT01808508 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham or placebo continuous positive airway pressure
Description: Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
Study NCT03829527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychological intervention combining a standardized treatment manual with a smartphone application
Study NCT00098839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epratuzumab
Description: Given IV
Study NCT02585375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost 50µg/ml
Study NCT01693016 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: non-invasive measurement of Hb
Study NCT01693016 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: taking blood samples
Study NCT02585375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preserved latanoprost 0.005%
Study NCT01465048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoites 2sites
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
Study NCT01321879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: 10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
Study NCT00780338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assets Getting To Outcomes
Description: Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
Study NCT00780338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assets Getting To Outcomes
Description: Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
Study NCT04000139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized anthocyanin-rich extract
Description: 3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
Study NCT04000139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
Study NCT00977093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfusion CMR for detection of coronary artery disease
Description: Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
Study NCT00977093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfusion cardiac magnetic resonance imaging
Description: Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
Study NCT01465048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoites 1 site
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
Study NCT01465048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoites 1site
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
Study NCT02980939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iv fluid infusion
Description: Intravenous isotonic saline infusion
Study NCT02980939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: iv fluid infusion
Description: Intravenous isotonic saline infusion
Study NCT03296904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLs++
Description: Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
Study NCT04045405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDR132L
Description: i.v. administration
Study NCT04045405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CDR132L
Description: i.v. administration
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00098839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00098839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT03833284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participant Barriers to TVU Screening
Description: Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
Study NCT03833284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Barriers to TVU Screening
Description: Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
Study NCT03897972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-personalised diet advice delivered via the eNutri app (control)
Description: Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
Study NCT03897972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised diet advice delivered via the eNutri app (intervention)
Description: Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
Study NCT05329597 — intervention group
Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping is performed using the subjects' blood cells
Study NCT04935151 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: holmium laser enucleation of the prostate
Description: cystoscopic transurethral enucleation of the prostate using Holmium laser
Study NCT04935151 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar resection of the prostate
Description: cystoscopic transurethral resection of the prostate using bipolar energy
Study NCT01340976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2787106
Description: Administered IV.
Study NCT01340976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplementation
Description: Administered orally.
Study NCT02897596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/d 8 weeks
Description: Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
Study NCT02897596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/d 8 weeks
Description: Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
Study NCT02897596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/d 12 weeks
Description: Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
Study NCT02897596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/d 12 weeks
Description: Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
Study NCT02567396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02567396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01015118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator to BIBF 1120
Study NCT02567396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT01015118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (standard chemo-therapy)
Study NCT01015118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
Study NCT03341052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Diet
Description: The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
Study NCT01015118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (standard chemo-therapy)
Study NCT03341052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Fat Diet
Description: The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
Study NCT01015118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (standard chemo-therapy)
Study NCT01015118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (standard chemo-therapy)
Study NCT03341052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
Study NCT02953821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: 1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
Study NCT02953821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: 1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
Study NCT00782210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients
Study NCT03626246 — intervention group
Intervention type: OTHER
Intervention: Kidney disease
Description: Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~* Bone density (DXA)~* Thoracic and lumbar spine plain films.~* HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~* Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~* Measure levels of Advanced Glycation End products (AGEs) in the skin.
Study NCT04507646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True auricular acupuncture
Description: The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
Study NCT04507646 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham auricular acupuncture
Description: The participant in control group will receive acupuncture on ineffective point at ear.
Study NCT00782210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
Study NCT04400097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suture
Description: suture methods of autograft conjunctival transplantation
Study NCT04400097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture
Description: suture methods of autograft conjunctival transplantation
Study NCT03701516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A with novel molding process
Description: TEST Lens
Study NCT04634292 — intervention group
Intervention type: BEHAVIORAL
Intervention: EEG
Description: EEG + walking task + auditory task
Study NCT02627859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane SJ
Description: 1ml single intra-articular injection in ankle
Study NCT03701516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A with current molding process
Description: CONTROL Lens
Study NCT04486573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac Magnetic Resonance Imaging
Description: A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
Study NCT01539707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
Study NCT03461653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine counselling
Description: women on web counselling
Study NCT03950817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg
Description: Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
Study NCT03950817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg
Description: Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
Study NCT03950817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
Description: Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
Study NCT03564678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Given IV
Study NCT03564678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B Complex
Description: Given PO
Study NCT04070157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
Study NCT04070157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.